Notably, almost all brain tumour types exhibit significantly elevated CD47 expression.420 As a result, CD47-targeted therapies have emerged to block the CD47-SIRPα interaction, enhancing immune recognition and enabling the immune system to attack cancer cells more effectively. This evidence concerns the gene CD47 and brain neoplasm.